Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicente Valero

Showing results (1-10 of 359) with videos related to

Pageof 36
Sort By:
Oncology (Williston Park, N.Y.)|July 11, 2002
Primary chemotherapy with docetaxel for the management of breast cancerVicente Valero
Clinical Breast Cancer|October 27, 2012
Managing ixabepilone adverse events with dose reductionVicente Valero
Chinese Clinical Oncology|January 12, 2022
What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative reviewDanielle B Zakon, Vicente Valero
Pharmacotherapy|August 19, 2003
Capecitabine-induced pancreatitisKellie L Jones, Vicente Valero
Journal of Thoracic Disease|March 14, 2014
Surgical indications and optimization of patients for resectable esophageal malignanciesJoshua C Grimm, Vicente Valero, Daniela Molena
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Emerging targeted therapies for breast cancerRicardo H Alvarez, Vicente Valero, Gabriel N Hortobagyi
Biophysical Journal|August 12, 2008
Tethering forces of secretory granules measured with optical tweezersVicente Valero, Thomas Nevian, Dominik Ho, et al.
The Lancet. Oncology|April 7, 2005
Docetaxel for treatment of solid tumours: a systematic review of clinical dataAlberto Montero, Frank Fossella, Gabriel Hortobagyi, et al.
Annals of Medicine|May 19, 2011
Ixabepilone for the treatment of breast cancerRicardo H Alvarez, Vicente Valero, Gabriel N Hortobagyi
Journal of Hepatocellular Carcinoma|August 11, 2016
Emerging role of Hpo signaling and YAP in hepatocellular carcinomaVicente Valero, Timothy M Pawlik, Robert A Anders
Pageof 36

Showing results (1-10 of 359) with videos related to

Sort By:
Pageof 36
Oncology (Williston Park, N.Y.)|July 11, 2002
Primary chemotherapy with docetaxel for the management of breast cancerVicente Valero
Clinical Breast Cancer|October 27, 2012
Managing ixabepilone adverse events with dose reductionVicente Valero
Chinese Clinical Oncology|January 12, 2022
What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative reviewDanielle B Zakon, Vicente Valero
Pharmacotherapy|August 19, 2003
Capecitabine-induced pancreatitisKellie L Jones, Vicente Valero
Journal of Thoracic Disease|March 14, 2014
Surgical indications and optimization of patients for resectable esophageal malignanciesJoshua C Grimm, Vicente Valero, Daniela Molena
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Emerging targeted therapies for breast cancerRicardo H Alvarez, Vicente Valero, Gabriel N Hortobagyi
Biophysical Journal|August 12, 2008
Tethering forces of secretory granules measured with optical tweezersVicente Valero, Thomas Nevian, Dominik Ho, et al.
The Lancet. Oncology|April 7, 2005
Docetaxel for treatment of solid tumours: a systematic review of clinical dataAlberto Montero, Frank Fossella, Gabriel Hortobagyi, et al.
Annals of Medicine|May 19, 2011
Ixabepilone for the treatment of breast cancerRicardo H Alvarez, Vicente Valero, Gabriel N Hortobagyi
Journal of Hepatocellular Carcinoma|August 11, 2016
Emerging role of Hpo signaling and YAP in hepatocellular carcinomaVicente Valero, Timothy M Pawlik, Robert A Anders
Pageof 36